文献速递产科母胎医学

血管生成标志物谱用于胎儿生长受限患者的风险分层

Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-05-12

这项前瞻性观察队列研究纳入45例24-37周单胎胎儿生长受限孕妇,采用sFlt-1/PlGF比值38为界值进行风险分层。比值≥38组诊断子痫前期比例更高、34周和37周前早产率更高、新生儿出生体重更低、从检测到分娩时间更短。sFlt-1/PlGF比值或可作为识别子痫前期及随后早产风险患者的潜在生物标志物。

要点

  • sFlt-1/PlGF比值≥38与子痫前期诊断比例更高相关
  • 高比值组34周和37周前早产率更高且新生儿出生体重更低
  • 高比值组从检测到分娩时间更短

核心结论

  • 在胎儿生长受限患者中,sFlt-1/PlGF比值可能作为识别子痫前期及随后早产风险患者的潜在生物标志物。

研究设计与样本

  • 前瞻性观察性队列研究,在单一三级医院进行,纳入45例24至37周单胎胎儿生长受限孕妇,共77次 encounters。
  • 排除有明确遗传或感染病因的胎儿生长受限或先天畸形妊娠。
  • 从入组到分娩每2周进行系列评估,分娩后双盲检测母血清sFlt-1和PlGF。

主要发现

  • 入组时中位(四分位1,四分位3)孕周为31.43(28.14-33.57)周。
  • 比值≥38组入组时收缩压和舒张压统计学显著升高(P=.02和P=.01)。
  • 与低比值组相比,高比值组子痫前期诊断比例更高、34周和37周前早产率更高、新生儿出生体重更小、从检测到分娩时间更短。
  • 两组基线特征包括子痫前期实验室检查和超声参数无显著差异。

关键数值与推荐

  • 使用既往发表的sFlt-1/PlGF比值界值38预测2周内子痫前期发生和严重程度以及不良母儿结局。
  • 低风险组比值<38,高风险组比值≥38。

临床怎么用

  • 对胎儿生长受限孕妇可考虑检测sFlt-1/PlGF比值,以辅助识别子痫前期和早产高风险患者。
  • 比值≥38提示需加强监测,关注血压升高及早产风险。

局限性

  • 样本量较小(45例患者,77次 encounters)。
  • 单中心研究,结果外推需谨慎。
  • 生物标志物检测在分娩后双盲进行,未用于临床实时决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel angiogenic biomarker profiles have demonstrated emerging evidence for predicting preeclampsia onset, severity, and adverse outcomes. Limited data exist in screening patients with fetal growth restriction for preeclampsia development using angiogenic biomarkers. OBJECTIVE: The objective of this study was to risk stratify patients with fetal growth restriction using a soluble fms-like tyrosine kinase-1 to placental growth factor ratio. Previously published cutoff of 38 was used to predict preeclampsia development and severity as well as adverse maternal or neonatal outcomes within a 2-week time period. STUDY DESIGN: This was a prospective observational cohort study performed in a single tertiary hospital. Patients with a singleton fetal growth restriction pregnancy between 24 and 37 weeks' gestation were evaluated using serial 2-week encounters from the time of enrollment to delivery. Pregnancies with proven genetic or infectious etiology of fetal growth restriction or congenital anomalies were excluded. Ultrasound growth and Doppler measurements were obtained at the start of every encounter with routine preeclampsia laboratory tests and blood pressure checks when clinically indicated. Maternal serum was collected for all serial encounters and measured for soluble fms-like tyrosine kinase-1 and placental growth factor after delivery in a double-blinded fashion. Maternal charts were reviewed for baseline demographic characteristics, pregnancy diagnoses and outcomes, and neonatal outcomes. RESULTS: A total of 45 patients were enrolled for a total of 77 encounters, with the median (quartile 1, quartile 3) gestational age of the study enrolled at 31.43 (28.14-33.57) weeks. Patients were divided into low-risk (ratio of <38) and high-risk (ratio of ≥38) groups. Baseline characteristics of patients did not show any marked differences, including preeclampsia labs or ultrasound parameters, between the 2 groups. Systolic and diastolic blood pressures upon enrollment were statistically elevated when soluble fms-like tyrosine kinase-1 to placental growth factor ratio was ≥38 (P=.02 and P=.01, respectively). Compared to patients with a low ratio, patients with a high ratio had a greater proportion of preeclampsia diagnosis, higher rates of preterm delivery under 34 and 37 weeks gestation, smaller neonatal birthweight, and a shorter time to delivery from testing to delivery. CONCLUSION: Among patients with fetal growth restriction, the soluble fms-like tyrosine kinase-1 to placental growth factor ratio may serve as a potential biomarker for identifying at risk patients for developing preeclampsia and subsequently preterm delivery.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Arenas GA, Tang NY, Mueller A, et al. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. Am J Obstet Gynecol MFM. 2021. PMID: 33991706. doi:10.1016/j.ajogmf.2021.100394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。